ALLOGEN BIOTECH LIMITED

Their core work

Allogen Biotech is a Dublin-based biotech SME developing consumer-facing diagnostic products that bring clinical testing capability into everyday settings. Their work focuses on translating diagnostic concepts into compact, low-cost devices that non-specialists can use without clinical infrastructure. Their two H2020 feasibility projects covered a rapid consumer test for gluten detection in food and a skin-patch system for allergy diagnostics — both targeting the same fundamental problem: making reliable diagnostic testing accessible and affordable outside the clinic. They appear to operate as a product development company, taking an identified diagnostic need through technical and commercial feasibility before seeking scale-up investment.

What they specialise in

How they've shifted over time

Both projects fall within a short 2016–2018 window, too close together to show a deep trend, but the direction is visible. The 2016 project (RAD) was rooted in food safety — detecting gluten in food products — placing the company squarely in the food and consumer testing space. By 2018, ARM-B had moved into medical diagnostics, specifically skin allergy screening, suggesting a deliberate expansion from food-sector testing into the broader consumer health market. The consistent thread across both is miniaturised, accessible diagnostics: the technology domain appears stable while the application markets are broadening.

Allogen Biotech is moving from food safety diagnostics toward consumer health diagnostics, suggesting future projects are likely to sit at the intersection of allergy, immunology, and point-of-care testing rather than in food safety specifically.

How they like to work

Allogen Biotech has acted as sole coordinator on both H2020 grants, with zero recorded consortium partners — consistent with the SME Phase 1 scheme, which is designed for solo SME applicants testing commercial viability rather than building research consortia. This means their EU project experience is entirely product-development and feasibility work, not multi-partner coordination. Any future consortium role would represent their first experience working within a multi-organisation structure, which is worth factoring in when assessing them as a consortium partner.

Allogen Biotech has no recorded H2020 consortium partners and no cross-border collaborations within the programme. Their EU engagement has been entirely as a solo applicant, so their documented research network is effectively limited to their Dublin base.

What sets them apart

Allogen Biotech occupies a narrow but commercially relevant niche: consumer-grade diagnostics that sit at the boundary between food safety, allergy medicine, and point-of-care health testing. Unlike academic spinouts, they pursued feasibility funding specifically to validate commercial viability — both projects were explicitly scoped as technical and business feasibility studies, not research. For a consortium needing an SME partner with demonstrated interest in bringing diagnostics to market rather than publishing results, they represent that profile, even if their track record is limited.

Highlights from their portfolio

• RAD
  One of relatively few H2020 SME-1 projects targeting rapid consumer-level gluten detection, bridging food safety regulation and the fast-growing celiac and gluten-intolerance market.
• ARM-B
  The allergy diagnostics patch concept — compact, wearable, low-cost — represents an ambitious product vision for a two-person-scale SME, and signals ambition beyond pure food safety into consumer health devices.